M&A Deal Summary

Vyant Bio Acquires vivoPharm Pty

On August 14, 2017, Vyant Bio acquired life science company vivoPharm Pty from Protea Biosciences Group for 12M USD

Acquisition Highlights
  • This is Vyant Bio’s 3rd transaction in the Life Science sector.
  • This is Vyant Bio’s largest (disclosed) transaction.
  • This is Vyant Bio’s 1st transaction in Australia.

M&A Deal Summary
Date 2017-08-14
Target vivoPharm Pty
Sector Life Science
Buyer(s) Vyant Bio
Sellers(s) Protea Biosciences Group
Deal Type Divestiture
Deal Value 12M USD

Target

vivoPharm Pty

Bundoora, Australia
website
vivoPharm Pty Ltd. is a provider of proprietary preclinical oncology and immuno-oncology services, offering integrated service in different disease areas to the biotechnology and pharmaceutical industries. vivoPharm Pty Ltd. was established in 2003 and is based in Bundoora, Australia.

Search 193,711 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Vyant Bio

Cherry Hill, New Jersey, United States

website

Category Company
Founded 1999
Sector Life Science
Employees34
Revenue 1M USD (2021)
DESCRIPTION

Vyant Bio is a drug discovery and preclinical oncology DNA-based cancer diagnostics and services medical institutions around the world. Vyant Bio's tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital, and HPV-associated cancers. Vyant Bio also offers a range of non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals as well as biopharma and biotech. Vyant Bio was founded in 1999 and is based in Cherry Hill, New Jersey.

DEAL STATS #
Overall 3 of 4
Sector (Life Science) 3 of 4
Type (Divestiture) 1 of 1
Country (Australia) 1 of 1
Year (2017) 1 of 1
Size (of disclosed) 1 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2014-06-23 Gentris

Morrisville, North Carolina, United States

Gentris LLC is a provider of superior quality pharmacogenomics, genotyping and biorepository services to the pharmaceutical and biotech industries.

Buy $5M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2019-07-15 Cancer Genetics - Biopharma Services Business

New Jersey, United States

Cancer Genetics, Inc. - Biopharma Services Business is a provider of molecular and biomarker-based tests for oncology and immuno-oncology drug development customers operating out of existing laboratories in Rutherford, NJ and Research Triangle Park, NC.

Sell -

Seller(S) 1

SELLER

Protea Biosciences Group

Morgantown, West Virginia, United States

website

Category Company
Founded 2001
Sector Information Services
Employees39
Revenue 1M USD (2014)
DESCRIPTION

Protea Biosciences Group, Inc. is a molecular information company providing innovative bioanalytical solutions to the pharmaceutical, agricultural and life science industries.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
Country (Australia) 1 of 1
Year (2017) 1 of 1
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2015-04-07 vivoPharm Pty

Bundoora, Australia

vivoPharm Pty Ltd. is a provider of proprietary preclinical oncology and immuno-oncology services, offering integrated service in different disease areas to the biotechnology and pharmaceutical industries. vivoPharm Pty Ltd. was established in 2003 and is based in Bundoora, Australia.

Buy -
Mergr

Product

Company

Legal